Keep the cat, change the care pathway: A transformational approach to managing Fel d 1, the major cat allergen

• Published in: Allergy (Copenhagen) Vol. 74; no. S107; pp. 5 - 17
• Main Authors: Satyaraj, Ebenezer, Wedner, Harold James, Bousquet, Jean
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.10.2019; Wiley; John Wiley and Sons Inc
• Subjects: Allergens; Allergies; Allergology; Antibodies; anti‐Fel d1 IgY; Asthma; Avoidance; blocking antibodies; cat allergies; Cats; Diagnosis; Exposure; Fel d 1; Immunology; Immunotherapy; Life Sciences; Molecular biology; Nose; Pets; Publication of this supplement is made possible by the Purina Institute; Rhinitis; Risk factors; Supplement; blocking antibodies; cat allergies; Fel d 1; anti-Fel d1 IgY; allergens
• ISSN: 0105-4538; 1398-9995
• DOI: 10.1111/all.14013

Background Allergies to cats are the most common animal‐origin allergy, and affect approximately 1 in 5 adults worldwide. The prevalence of allergy to furry animals has been increasing, and allergy to cats is a major risk factor for the development of asthma and rhinitis. The diagnosis of cat allergy is now well established. The exact significance of component‐resolved diagnosis in the diagnosis of cat allergy remains to be fully understood. Allergen avoidance is effective but often has a psychologic impact. Allergen immunotherapy is not well demonstrated. There is a need for innovative approaches to better manage cat allergens. Next‐generation care pathways for asthma and rhinitis will define the place of cat allergen avoidance. Methods and Results This manuscript, based on content presented at the European Academy of Allergy and Clinical Immunology Congress 2019, provides information on the prevalence and impact of cat allergies and the molecular biology of Fel d 1, the major cat allergen. Discussion The authors present the scientific basis of a novel care pathway that utilizes anti‐Fel d 1 IgY antibodies to safely and effectively neutralize Fel d 1 after its production by the cat but before human exposure. Conclusion Efficacy of a feline diet with an egg product ingredient containing anti‐Fel d 1 IgY antibodies was demonstrated in vitro, ex vivo, and in vivo, and further validated by a pilot exposure study involving cat‐allergic human participants.